I. A. Montgomery

Beneficial effects of the novel cholecystokinin agonist (pGlu-Gln)-CCK-8 in mouse models of obesity/diabetes

Nigel Irwin, Pamela Frizelle, I. A. Montgomery et al. · Diabetologia · 2012 · 66 citations · Full text

Obesity, Metabolic Syndrome, Molecular Pharmacology +12

Comparison of independent and combined metabolic effects of chronic treatment with ( <scp>pGlu</scp> ‐Gln)‐ <scp>CCK</scp> ‐8 and long‐acting <scp>GLP</scp> ‐1 and <scp>GIP</scp> mimetics in high fat‐fed mice

Nigel Irwin, Kerry Hunter, I. A. Montgomery et al. · Diabetes Obesity and Metabolism · 2013 · 35 citations

Active immunization against (Pro ³ )GIP improves metabolic status in high‐fat‐fed mice

I. A. Montgomery, Nigel Irwin, Peter R. Flatt · Diabetes Obesity and Metabolism · 2010 · 27 citations

Comparison of the independent and combined metabolic effects of subchronic modulation of CCK and GIP receptor action in obesity-related diabetes

Nigel Irwin, I. A. Montgomery, Finbarr O’Harte et al. · International Journal of Obesity · 2012 · 14 citations

Obesity, Metabolic Syndrome, Subchronic Modulation +13

Comparison of the metabolic effects of sustained CCK1 receptor activation alone and in combination with upregulated leptin signalling in high-fat-fed mice

Nigel Irwin, I. A. Montgomery, Peter R. Flatt · Diabetologia · 2013 · 12 citations · Full text

Obesity, Metabolic Syndrome, Energy Homeostasis +14